Blogs
One bulk batch. Multiple markets. A moving forecast.
A manufacturing order was placed months ago. The quantities reflected the forecast, and the batch was expected to supply several country markets.
Now one market needs less. Another needs more. Some stock is approaching expiry, while a new order is being considered elsewhere. The original supply is still on its way.
For the planning team, the questions are immediate: can the batch be split differently? Can available stock cover the requirement? Is repacking possible? Or is another CMO order really necessary?
Each decision affects the others. A change that protects service in one market may leave excess inventory in another. A larger order may satisfy a partner’s batch rules but create stock that cannot be sold within its remaining shelf life.
Where product eligibility and approved packaging arrangements allow, a common bulk batch can be allocated to multiple market-specific presentations. Order quantities, market allocations and available inventory therefore need to be evaluated together. The financial priorities are to reduce write-offs, avoid unnecessary orders and improve allocation of committed bulk.
What Is CMO Planning and Optimization?
A Contract Manufacturing Organization (CMO) manufactures products on behalf of another company. For the pharmaceutical company placing the order, CMO planning connects external manufacturing requirements with demand, inventory and market needs.
CMO Planning and Optimization evaluates how much to order, how to allocate shared bulk across country-specific packs, and whether existing inventory can meet demand. It considers partner capacity, batch rules, lead times, packaging constraints, product and market eligibility, and shelf life.
Optimization means evaluating feasible alternatives against defined objectives and constraints. In this context, it helps determine which combination of orders, allocations and inventory decisions best balances cost and service.
Why Market-Level Allocation Matters
Consider an illustrative situation: a bulk batch is intended for three country markets. Before packaging is finalized, demand falls in one market and rises in another. The total quantity may still be appropriate, but the planned country split may no longer match demand.
Market-level allocation determines how much of that shared batch is assigned to each country-specific product. Keeping the original allocation could leave one market with excess stock and another with a shortage.
Changing the split may help, but the alternatives depend on packaging requirements, market eligibility, remaining shelf life and partner constraints. Available stock also needs to be checked: inventory somewhere in the network is only useful if it can meet the relevant market’s requirements in time.
Can usable stock meet the requirement? Can available bulk be packaged for the required market, or can finished stock be repacked where authorized? Can supply be rebalanced across markets? These alternatives need to be compared with replenishment on both cost and service.
Three Financial Value Levers for CMO Planning
Reduce write-offs
Align orders and feasible market allocations with forecast changes and remaining shelf life, helping avoid inventory that cannot be sold in time.
Avoid unnecessary orders
See usable stock across the network before placing another order. Compare ordering, repacking and rebalancing options based on cost and service, so existing supply is used wherever feasible.
Improve allocation of committed bulk
Allocate shared bulk across country-specific packs within each partner's batch-size and packaging constraints. Where feasible, revisit allocations as demand changes, while considering market requirements and remaining shelf life. For products with longer shelf lives, better allocation can also help prevent lost sales by directing available supply to markets where it is needed.
Inventory may require a write-down when its net realizable value falls below cost, or a full write-off when no recoverable value remains. An allocation mismatch does not automatically mean the stock has lost its value. Bulk allocation efficiency reflects how much committed production can be assigned to eligible market demand without creating avoidable excess. Together with avoidable orders, these provide a practical starting point for assessing the financial impact of CMO decisions.
The Decision Does Not Stop When the Order Is Placed
When CMO orders or manufacturing slots are committed months before delivery, demand and inventory conditions may change before supply becomes available. Planning therefore needs to continue across three stages.
| Stage | Planning question | What needs to be evaluated? |
|---|---|---|
| Before the order | Do we need additional supply? | Stock, safety levels, incoming and expiring inventory across plants, CMOs and markets; available stock or repacking that could avoid an order. |
| At the order | What quantity should we commit to, and which market allocations must be fixed now versus later? | CMO order quantities, partner commitments, packaging capacity, and opportunities to defer eligible market-specific allocations until demand becomes clearer. |
| After the order | What can change as the forecast moves? | Feasible allocations, remaining shelf life, and stock, delay and supply exceptions. |
Not every commitment can be changed. The task is to identify which alternatives remain feasible and understand their consequences before making the next decision.
The ICRON overview for regulated supply chains: what it plans, where it fits alongside your existing systems, and how decisions stay governed.
Get the brochureWhat Do AI and AI Agents Add to Planning?
AI can support the analysis of planning information: helping teams investigate exceptions, explore scenarios and understand what has changed. An exception is a condition that needs attention, such as a supply delay or an inventory position that no longer matches demand.
AI agents are software capabilities that carry out defined tasks within a decision process. Their activities are governed by business rules, policies and constraints. In planning, they can support the work of evaluating information and coordinating decisions with the steps required for execution. Where integrations are configured, requests or operational events can come from planners, other agents, manufacturing execution systems (MES), ERP, or other connected applications. Within defined authority, agents can assess those inputs, gather relevant context, coordinate workflows, adjust planning scenarios, run or rerun optimization, compare and retain results, and execute permitted actions or escalate decisions requiring approval.
Optimization evaluates whether the alternatives satisfy the modeled requirements. For a CMO decision, those requirements include shelf life, market eligibility, packaging, partner capacity and batch rules.
Governance defines which decisions require review, approval, override or escalation. This connects the use of AI and AI agents with the controls needed to act on a recommendation.
How ICRON Supports CMO Planning and Optimization
ICRON’s CMO Planning and Optimization capability extends Customer Centric Supply Chain Planning to external manufacturing networks. Powered by the AI-Native Decision Execution Hub, it works alongside existing planning and ERP systems to optimize CMO orders, batch allocation and inventory decisions.
The Hub connects planning, optimization, governance and execution. Its specialized AI agents support decision processes within defined business rules and policies, with people involved where judgment and accountability are required.
Bring together forecasts, stock, open orders, material needs and partner rules.
Evaluate orders, shared bulk allocation, repacking, rebalancing and shelf-life trade-offs.
Review, approve, override and trace decisions.
Hand approved decisions back into existing workflows.
Governance rules determine where approval, override or escalation is required.
For CMO planning, the outputs can include proposed orders, market-level batch splits, repack or rebalance options, and updated partner plans. Proposed quantities can be traced to finished-good demand and the related intermediate, active pharmaceutical ingredient (API), and packaging needs.
ICRON provides explainable recommendations that planners can review and approve. Each decision and its rationale can be captured and traced, while governance rules determine which routine actions may proceed within defined authority and which require human approval. Routine cases can move toward exception-based execution, where planners focus on decisions that require attention.
Build the Business Case With Your Own Data
The financial case starts with the company’s own exposure. An ICRON CMO value workshop uses three inputs:
- Annual write-offs on externally sourced SKUs.
- The value of stock in the wrong market.
- The number of CMO batches ordered each year.
These inputs help assess where better orders, batch allocation and use of available inventory could create value. Assumptions are tested against actual operating constraints rather than converted into preset savings claims. Service continuity and planner productivity are supporting benefits.
Where Could Your CMO Plan Improve?
Bring last year's write-offs or backorders. We'll use your own data to explore where better ordering, repacking and market allocation decisions could reduce waste, protect service and make better use of existing supply.
Frequently Asked Questions
What is CMO planning for pharmaceutical companies?
It connects orders placed with external manufacturers to demand, inventory and market requirements. The decisions include order quantities, shared batch allocation, repacking and replenishment.
What is market-level batch allocation?
It is the assignment of a shared bulk batch to country-specific products, taking account of demand, packaging requirements, market eligibility and remaining shelf life.
What is the role of AI agents in planning?
AI agents support defined tasks within decision processes. In ICRON’s AI-Native Decision Execution Hub, specialized AI agents support planning, optimization, governance and execution within business rules, policies and constraints.
How are decisions controlled?
Governance determines where review, approval, override or escalation is required. For CMO planning, planners can review, approve or override recommendations; routine cases can move toward exception-based execution.
Does ICRON offer CMO Planning and Optimization?
Yes. The capability supports CMO orders, shared bulk allocation and inventory decisions alongside existing planning and ERP systems.
Can repacking help avoid a new order?
Where product approvals, packaging capabilities, timing, and remaining shelf-life requirements allow, market-specific packaging of available bulk or authorized repacking of finished stock can be compared with reallocation and new manufacturing orders.
Can allocations be reviewed after an order is placed?
Yes. Feasible allocations can be re-evaluated as forecasts change. The available alternatives depend on partner commitments and the relevant operational constraints.